Health profesionals

 

 

 

 

 

 

Publish studies and talks from different magazines and conventions:

Eur J Obstet Gynecol Reprod Biol. 2007;130(1):140-1.

Eur J Obstet Gynecol Reprod Biol. 2007;130(1):140-1.

“DT56a has anti-estrogenic properties in the breast tissue…”
Clin. and Exp. Ob. & Gyne. 2004;31(2):123-6.

Clin. and Exp. Ob. & Gyne. 2004;31(2):123-6.

” …significant reduction in the Kupperman index following 12 weeks of treatment, which was sustained throughout the 12 months of
Menopause. 2003;10(6):522-5.

Menopause. 2003;10(6):522-5.

“Femarelle treatment in postmenopausal women increases BMD without unwanted estrogenic effect.”
J Steroid Biochem Mol Biol.. 2006;98(1):90-6

J Steroid Biochem Mol Biol.. 2006;98(1):90-6

“DT56a … unique nature compared to the compounds currently used for postmenopausal osteoporosis by being bone-forming and not only an anti-resorptive
Climacteric. 2015;18(6):813-6

Climacteric. 2015;18(6):813-6

“Treatment with DT56a resulted in a significant reduction in the number and intensity of hot flushes in postmenopausal women… observed within the
BJOG. 2005;112(7):981-5

BJOG. 2005;112(7):981-5

“DT56a prevents postmenopausal osteoporosis.”
Menopause 2011;18(3):285-288

Menopause 2011;18(3):285-288

“Femarelle … inhibits menopausal symptoms without thrombogenicity…”
NAMS Annual Congress 2011, book of abstracts

NAMS Annual Congress 2011, book of abstracts

” DT56a was effective against symptomatic vulvo-vaginal atrophy (vaginal dryness)…”
J Endocrinol Invest. 36(7):521-6

J Endocrinol Invest. 36(7):521-6

“DT56a decreased menopausal symptoms significantly and in the same degree as HT.”